Predictive Oncology Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $77.7 million for the quarter, compared to a loss of $3.1 million in the same period last year. For the nine months ending September 30, 2025, the net loss totaled $82.2 million, a substantial increase from $10.5 million in the prior year. Revenue for the third quarter was $3,618, a slight decrease from $3,907 in the previous year, while year-to-date revenue increased to $116.6 million from $76.0 million, primarily due to the completion of a tumor-specific 3D model.
The company's financial position has deteriorated, with total assets dropping to $3.1 million from $5.0 million at the end of 2024. Current liabilities surged to $80.6 million, up from $5.2 million, largely due to a derivative liability of $74.4 million related to a recent cryptocurrency private placement. This drastic increase in liabilities has resulted in a stockholders' deficit of $77.4 million, compared to a deficit of $202,610 at the end of 2024.
In terms of strategic developments, Predictive Oncology has adopted a new Treasury Strategy focused on the Aethir token (ATH), which aims to create a Strategic Compute Reserve. The company has begun accumulating ATH and plans to use it to fund its operations and investments. On October 7, 2025, Predictive Oncology closed two private placements, raising approximately $50.8 million in cash and receiving ATH with a notional value of $292.7 million. This funding is expected to support the company's ongoing operations for at least the next 12 months.
Operationally, the company has undergone significant changes, including the discontinuation of its Eagan operating segment, which has been classified as a discontinued operation. This segment's assets were sold to DeRoyal Industries for $625,000, and the company now focuses solely on its AI-driven oncology drug development business. The workforce has also been reduced, contributing to a decrease in general and administrative expenses, although legal fees related to ongoing litigation have increased.
Looking ahead, Predictive Oncology faces substantial challenges, including the need to generate sufficient revenue to cover its operating costs and the volatility associated with its digital asset strategy. The company has expressed uncertainty regarding its ability to continue as a going concern, emphasizing the importance of securing additional financing and successfully implementing its Treasury Strategy to stabilize its financial situation.
About Predictive Oncology Inc.
Predictive Oncology Inc. leverages artificial intelligence and a proprietary biobank of over 150,000 tumor samples to support cancer drug discovery and development. The company provides AI-driven predictive models, tumor-specific 3D cell culture models, and clinical tumor profiling tests. Its core markets include biopharmaceuticals, diagnostics, and healthcare providers, focusing on improving drug success rates, personalized treatments, and efficient oncology research.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.